Funder
Fondazione Umberto Veronesi
Associazione Italiana per la Ricerca sul Cancro
Ministero della Salute
Reference82 articles.
1. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer;Browder;Cancer Res.,2000
2. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity;Klement;J. Clin. Investig.,2000
3. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice;Hanahan;J. Clin. Investig.,2000
4. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells;Bertolini;Cancer Res.,2003
5. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response;Perroud;Cancer Chemother. Pharmacol.,2016